[1] VAN DE RIJN M,LOMBARD C M,ROUSE R V.Expression of CD34 by solitary fibrous tumors of the pleura,mediastinum,and lung[J]. Am J Surg Pathol,1994,18( 8) : 814-820. [2] JAASKELAINEN J, SERVO A, HALTIA M, et al.Meningiomas and their surgical treatment[M]. Orlando: Saundem Company,1991: 78. [3] RAMAKRISHNA R, ROSTOMILY R, SEKHAR L, et al.Hemangiopericytoma: radical resection remains the cornerstone of therapy[J]. J Clin Neurosci,2014,21(4): 612-615. [4] 邬迎喜,薛亚飞,赵天智,等.腰椎管内髓外硬膜下及硬膜外血管周细胞瘤 1 例[J]. 中国微侵袭神经外科杂志,2016, 21(2): 178. [5] ZHANG X L, CHENG H X, BAO Y, et al.The application value of STAT6 immunohistochemical staining in the diagnosis of solitary fi-broma /meningeal hemangiomas[J]. Chin J Pathol,2016,45( 2) : 97-101. [6] LOUIS D N, PERRY A, RE G, et al.The 2016 World Health Organi- nation classification of the central nervous system: a summary[J].Acta Neuropathol,2016,131( 6) : 803-820. [7] CLARENCON F, BONNEVILLE F, ROUSSEAU A, et al.Intracranial solitary fibrous tumor: imaging findings[J]. Eur J Radiol, 2011,80(2):387-394. [8] PARK B J, KIM Y I, HONG Y K, et al.Clinical analysis of intracranial hemangiopericytoma[J]. J Korean Neurosurg Soc, 2013, 54(4):309-316. [9] FLETCHER C D, BRIDGE J A, HOGENDOORN P, et al.WHO classification of tumors of soft tissue and bone[M].Lyon: IARC Press, 2013: 305-310. [10] LOUIS DN, PERRY A, WESSELING P, 等. 2021年WHO中枢神经系统肿瘤分类概述[J]. 放射学实践, 2021,36(7):818-831. [11] 张雷, 庄雄杰, 汪敬群, 等. 中枢神经系统孤立性纤维瘤的影像学表现[J]. 中国医学影像技术, 2014, 30(1):20-23. [12] 徐万里, 郑屹峰, 方炜. 颅内孤立性纤维肿瘤的 MRI 特征与病理分析[J]. 实用放射学杂志, 2018, 34(1):19-22. [13] CHEN L F, YANG Y, YU X G, et al.Multimodal treatment and management strategies for intracranial hemangiopericytoma[J]. J Clin Neurosci, 2015, 22(4):718-725. [14] 祝跃明,金中高,姚振威,等.颅内血管外皮细胞瘤的CT和MRI表现[J]. 实用肿瘤学杂志,2007,21( 1) : 58-59. [15] 陈谦,戴建平,高培毅.颅内血管外皮细胞瘤与脑膜瘤的MR影像对照研究[J]. 中华放射学杂志,2003,37( 6) : 519-524. [16] 刘天艺,仲雷.恶性孤立性纤维性肿瘤的临床病理特征分析并文献复习[J]. 现代肿瘤医学,2020,28( 4) : 635-638. [17] OISHI M, FUJISAWA H, TSUCHIYA K, et al.The importance of STAT6 in a schwannoma-like grade Ⅲ solitary fibrous tumor/he- mangiopericytoma located in the cerebellopontine angle and Meckel’s cave[J]. World Neurosurg,2020,141: 500-506. [18] 陈净慈,陈杰.CD34 在软组织肿瘤中的表达及病理意义[J]. 中华病理学杂志,2020,49( 10) : 1088-1092. [19] 丁志燕,王艳芬,王璇,等.信号转导及转录激活因子6在孤立性纤维性肿瘤中的表达和意义[J]. 中华病理学杂志, 2017,46( 4) : 235-239. [20] GERAMIZADEH B, MARZB M, CHURG A.Role of immunohistochemistry in the diagnosis of solitary fibrous tumor,a review[J]. Iran J Pathol,2016,11(3):195-203. [21] PANG H, YAO Z, REN Y, et al.Morphologic patterns and imaging features of intracranial hemangiopericytomas: a retrospective anal- ysis[J]. Onco Targets Ther,2015,8: 2169-2178. [22] MARTIN-BROTO J, STACCHIOTTI S, LOPEZ-POUSA A, et al.Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(1):134-44. [23] WANG K, MEI F, WU S, et al.Hemangiopericytoma: incidence, treatment, and prognosis analysis based on SEER database[J]. BioMed Res Int, 2020,2020:2468320. [24] PARK M S, RAVI V, CONLEY A, et al.The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis[J]. Clin Sarcoma Res, 2013, 3(1):7. [25] CHAMBERLAIN M C, GLANTZ M J.Sequential salvage chemotherapy for recurrent intracranial hemangioperitoma[J]. J Clin Nerosci,2011, 18(11): 1500-1504. [26] STACCHIOTTI S, SIMEONE N, LO VULLO S, et al.Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study[J]. Euro J Cancer, 2019, 106: 225-233. |